Literature DB >> 27197615

Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis.

Zufeng Ding1,2, Shijie Liu1, Xianwei Wang1, Pankaj Mathur1, Yao Dai1, Sue Theus1, Xiaoyan Deng2, Yubo Fan2, Jawahar L Mehta1.   

Abstract

AIMS: The present study was designed to investigate a possible interaction between vascular smooth muscle cell (SMC)-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) and mitochondrial DNA (mtDNA) damage.
RESULTS: Treatment of cultured SMCs with the proinflammatory stimulus lipopolysaccharide (LPS) stimulated PCSK9 release and induced mtDNA damage. PCSK9 inhibition by its siRNA reduced, and its enhancement increased, mtDNA damage. Induction of mitochondria-derived reactive oxygen species (mtROS) (by rotenone, thenoyltrifluoroacetone, or antimycin A) enhanced mtDNA damage as well as PCSK9 release, suggesting a role of mtROS in PCSK9-mtDNA damage interplay. Induction of mtDNA damage (with the autophagy inhibitor, 3-methyladenine, or DNase II inhibition) enhanced PCSK9 expression, and inhibition of mtDNA damage (with the autophagy inducer, rapamycin) reduced PCSK9 expression, indicating bidirectional interplay between PCSK9 and mtDNA damage. Other studies showed that p38 MAPK is involved in PCSK9-induced mtDNA damage, and mammalian target of rapamycin activation plays a role in mtDNA damage-induced PCSK9 release. Functional impact of PCSK9-mtDNA damage cross-talk was evident in the form of SMC apoptosis, which was enhanced in cells treated with recombinant human PCSK9, but inhibited in cells treated with PCSK9 siRNA. Last, LPS administration in wild-type mice resulted in simultaneous PCSK9 release and mtDNA damage, but mtDNA damage was minimal in PCSK9-null mice given LPS. INNOVATION: Vascular SMC-derived PCSK9 induces mtDNA damage, and damaged mtDNA fragments stimulate PCSK9 release mediated, at least in part, by mtROS.
CONCLUSIONS: These observations suggest positive feedback interplay between SMC-derived PCSK9 and mtDNA damage in the proinflammatory milieu involving mtROS. This interaction results in cellular injury, characterized by apoptosis-a hallmark of atherosclerosis. Antioxid. Redox Signal. 25, 997-1008.

Entities:  

Keywords:  PCSK9; apoptosis; mtDNA damage; smooth muscle cells

Mesh:

Substances:

Year:  2016        PMID: 27197615     DOI: 10.1089/ars.2016.6631

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  20 in total

Review 1.  Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.

Authors:  Angelos D Karagiannis; Martin Liu; Peter P Toth; Shijia Zhao; Devendra K Agrawal; Peter Libby; Yiannis S Chatzizisis
Journal:  Curr Atheroscler Rep       Date:  2018-03-10       Impact factor: 5.113

2.  Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells.

Authors:  Yanqiang Zou; Zhang Chen; Xi Zhang; Jizhang Yu; Heng Xu; Jikai Cui; Yuan Li; Yuqing Niu; Cheng Zhou; Jiahong Xia; Jie Wu
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

Review 3.  PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery.

Authors:  Silvia Ortona; Chiara Barisione; Pier Francesco Ferrari; Domenico Palombo; Giovanni Pratesi
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

4.  Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines.

Authors:  Shijie Liu; Xiaoyan Deng; Peng Zhang; Xianwei Wang; Yubo Fan; Sichang Zhou; Shengyu Mu; Jawahar L Mehta; Zufeng Ding
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 10.787

5.  Dynamin-related protein 1 inhibition reduces hepatic PCSK9 secretion.

Authors:  Maximillian A Rogers; Joshua D Hutcheson; Takehito Okui; Claudia Goettsch; Sasha A Singh; Arda Halu; Florian Schlotter; Hideyuki Higashi; Lixiang Wang; Mary C Whelan; Andrew K Mlynarchik; Alan Daugherty; Masatoshi Nomura; Masanori Aikawa; Elena Aikawa
Journal:  Cardiovasc Res       Date:  2021-09-28       Impact factor: 10.787

6.  Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome.

Authors:  Kwi Hyun Bae; Sung Woo Kim; Yeon Kyung Choi; Jung Beom Seo; Namkyun Kim; Chang Yeon Kim; Won Kee Lee; Sungwoo Lee; Jung Guk Kim; In Kyu Lee; Jang Hoon Lee; Keun Gyu Park
Journal:  Diabetes Metab J       Date:  2018-05-02       Impact factor: 5.376

Review 7.  PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis.

Authors:  Qianyun Guo; Xunxun Feng; Yujie Zhou
Journal:  Front Genet       Date:  2020-09-23       Impact factor: 4.599

Review 8.  PCSK9 Biology and Its Role in Atherothrombosis.

Authors:  Cristina Barale; Elena Melchionda; Alessandro Morotti; Isabella Russo
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

Review 9.  The Vicious Cycle of Renal Lipotoxicity and Mitochondrial Dysfunction.

Authors:  Mengyuan Ge; Flavia Fontanesi; Sandra Merscher; Alessia Fornoni
Journal:  Front Physiol       Date:  2020-07-07       Impact factor: 4.566

10.  Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study.

Authors:  Gema Miñana; Julio Núñez; Antoni Bayés-Genís; Elena Revuelta-López; César Ríos-Navarro; Eduardo Núñez; Francisco J Chorro; Maria Pilar López-Lereu; Jose Vicente Monmeneu; Josep Lupón; Juan Sanchis; Vicent Bodí
Journal:  ESC Heart Fail       Date:  2020-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.